InsiderTrades.com logo
Oxana Beskrovnaya net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Oxana Beskrovnaya Biography and Net Worth

Chief Scientific Officer of Dyne Therapeutics
Oxana is an accomplished R&D leader with a strong track record of discovering and developing first-in-class therapeutics for rare genetic diseases. Prior to joining Dyne, Oxana served as head of musculoskeletal and renal research in Sanofi’s rare disease and neurological unit, advancing a pipeline of drug candidates using multiple therapeutic modalities, including nucleic acids, proteins and small molecules. Previously, she served in various capacities of increasing responsibility at Genzyme, managing research in genetics, disease mechanisms, target discovery/validation and translational biomarkers in rare renal, metabolic, skeletal and neuromuscular diseases. She has authored numerous patents, invited reviews, editorials, book chapters and original research articles in major scientific journals, including Nature, Nature Medicine, Cell and Molecular Cell. Oxana received her Ph.D. in genetics from Moscow Genetics Institute, followed by postdoctoral fellowship training in neuromuscular diseases at the Howard Hughes Medical Institute at the University of Iowa.

What is Oxana Beskrovnaya's net worth?

The estimated net worth of Oxana Beskrovnaya is at least $1.62 million as of March 11th, 2025. Dr. Beskrovnaya owns 195,840 shares of Dyne Therapeutics stock worth more than $1,621,555 as of April 4th. This net worth approximation does not reflect any other investments that Dr. Beskrovnaya may own. Additionally, Dr. Beskrovnaya receives a salary of $631,080.00 as Chief Scientific Officer at Dyne Therapeutics. Learn More about Oxana Beskrovnaya's net worth.

How old is Oxana Beskrovnaya?

Dr. Beskrovnaya is currently 63 years old. There are 7 older executives and no younger executives at Dyne Therapeutics. Learn More on Oxana Beskrovnaya's age.

What is Oxana Beskrovnaya's salary?

As the Chief Scientific Officer of Dyne Therapeutics, Inc., Dr. Beskrovnaya earns $631,080.00 per year. There are 2 executives that earn more than Dr. Beskrovnaya. The highest earning executive at Dyne Therapeutics is Ms. Susanna Gatti High M.B.A., Chief Operating Officer, who commands a salary of $754,100.00 per year. Learn More on Oxana Beskrovnaya's salary.

How do I contact Oxana Beskrovnaya?

The corporate mailing address for Dr. Beskrovnaya and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at ir@dyne-tx.com. Learn More on Oxana Beskrovnaya's contact information.

Has Oxana Beskrovnaya been buying or selling shares of Dyne Therapeutics?

Oxana Beskrovnaya has not been actively trading shares of Dyne Therapeutics within the last three months. Most recently, Oxana Beskrovnaya sold 2,153 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $11.38, for a transaction totalling $24,501.14. Following the completion of the sale, the insider now directly owns 195,840 shares of the company's stock, valued at $2,228,659.20. Learn More on Oxana Beskrovnaya's trading history.

Who are Dyne Therapeutics' active insiders?

Dyne Therapeutics' insider roster includes Oxana Beskrovnaya (Chief Scientific Officer), Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Johanna Friedl-Naderer (Chief Commercial Officer), Susanna High (COO), Carlo Incerti (Director), Dirk Kersten (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.

Are insiders buying or selling shares of Dyne Therapeutics?

During the last year, Dyne Therapeutics insiders bought shares 1 times. They purchased a total of 32,000 shares worth more than $1,057,280.00. During the last year, insiders at the sold shares 25 times. They sold a total of 388,416 shares worth more than $12,878,411.80. The most recent insider tranaction occured on March, 13th when insider Johanna Friedl-Naderer sold 143 shares worth more than $1,733.16. Insiders at Dyne Therapeutics own 20.8% of the company. Learn More about insider trades at Dyne Therapeutics.

Information on this page was last updated on 3/13/2025.

Oxana Beskrovnaya Insider Trading History at Dyne Therapeutics

See Full Table

Oxana Beskrovnaya Buying and Selling Activity at Dyne Therapeutics

This chart shows Oxana Beskrovnaya's buying and selling at Dyne Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Dyne Therapeutics Company Overview

Dyne Therapeutics logo
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $8.28
Low: $8.15
High: $9.40

50 Day Range

MA: $12.81
Low: $8.28
High: $16.76

2 Week Range

Now: $8.28
Low: $8.15
High: $47.45

Volume

2,602,714 shs

Average Volume

1,424,078 shs

Market Capitalization

$936.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11